Allergan reports positive clinical data for migraine therapy

Allergan has announced new clinical findings highlighting the promise of a new drug for the treatment of migraines.

Positive results from ACHIEVE I, the first of two pivotal phase III clinical trials evaluating the efficacy, safety and tolerability of the oral CGRP receptor antagonist ubrogepant, have been highlighted by the company this week.

Both doses showed a statistically significant greater percentage of ubrogepant patients achieving pain freedom at two hours after the initial dose compared to placebo, while a significantly greater percentage of ubrogepant patients also achieved absence of the most bothersome migraine-associated symptoms.

Additional results from this study will be released at upcoming scientific meetings throughout 2018, while results from the second phase III trial, ACHIEVE II , are expected in the first half of the year. 

David Nicholson, chief research and development officer at Allergan, said: "Allergan remains committed to identifying, developing and bringing to market therapies that address unmet need for patients suffering from this debilitating disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.